Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo Pharmaceuticals Inc.

Division of Endo International PLC
www.endo.com/endopharma/home

Latest From Endo Pharmaceuticals Inc.

Endo’s Generics Add $30m Due To COVID-19 Impact

Despite reporting 14% growth in the first quarter of 2020, Endo has forecast a downturn in the second quarter and has withdrawn its full-year financial guidance due to uncertainty regarding the continued impact of the coronavirus pandemic.

Strategy Sales & Earnings

Bayer, Curadev Enter ‘STING’ Pact Exploring Inflammatory Disease

Bayer and Curadev entered a research collaboration and license agreement to develop novel STING antagonists targeting inflammatory disease.

Companies Commercial

Pharma Enforcement Remains 'Priority Area' In FTC's 2021 Budget Request

US Federal Trade Commission has mainly focused in pay-for-delay cases over the past decade, but pricing strategies are an emerging area of attention; industry is paying close attention to potential enforcement in biosimilar market.

Enforcement Legal Issues

Intellipharmaceutics’ Oxycodone ER Returns To US FDA Panel Looking For Abuse-Deterrence Claim

Although abuse by intravenous route is expected to be deterred compared to immediate-release oxycodone, neither nasal nor oral abuse deterrence was demonstrated in two new human abuse potential studies, agency concludes; product has a new formulation and a new name, Aximris XR, since a 2017 AdComm.

Advisory Committees Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Endo International PLC
  • Senior Management
  • Contact Info
  • Endo Pharmaceuticals Inc.
    Phone: (484) 216-0000
    1400 Atwater Dr.
    Malvern, PA 19355
    USA
UsernamePublicRestriction

Register